TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35189082

Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablets (5 mg, 10 mg, 15 mg, 20 mg based on weight bands)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dolutegravir 25 mg film-coated tablets
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall safety evaluation
Number of subjects: 72
Study: 33503531

Group type: EXPERIMENTAL
Intervention: Intradermal sterile water injection (ISWI) combined with systemic intravenous dexketoprofen therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Systemic intravenous dexketoprofen therapy alone
Number of subjects: 112
Study: 36344654

Group type: EXPERIMENTAL
Intervention: Bevacizumab and Erlotinib (AE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bevacizumab (A)
Number of subjects: 60
Study: 34247300

Group type: EXPERIMENTAL
Intervention: Group psychoeducational intervention for grandparents; 6-hour intervention program.
Number of subjects: 120
Study: 32538561

Group type: EXPERIMENTAL
Intervention: PRP assisted reconstruction of 3‐strand peroneal longus tendons
Number of subjects: 58

Group type: COMPARATOR
Intervention: 4‐strand hamstring tendon reconstruction alone
Number of subjects: 58
Study: 35662124

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention mediated with new technologies (16 sessions including attention, executive function, and memory tasks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention
Number of subjects: 98
Study: 35550441

Group type: EXPERIMENTAL
Intervention: CD34+ selection and post‐transplantation cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus/methotrexate (Tac/MTX)
Number of subjects: 0
Study: 35815358

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: EudraVigilance
Number of subjects: 0
Study: 33663132

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32685542

Group type: EXPERIMENTAL
Intervention: Conbercept treatment (initial intravitreal injection followed by PRN strategy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conbercept treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 60
Study: 35393631

Group type: EXPERIMENTAL
Intervention: dupilumab ± topical corticosteroids
Number of subjects: 471
Study: 33947965

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32663479

Group type: EXPERIMENTAL
Intervention: Proprioceptive training program (twice weekly for 12 weeks, 55 minutes per session)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Proprioceptive training program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Physical therapy intervention program (45 minutes group + 100 minutes individual per week for 12 weeks)
Number of subjects: 42
Study: 34309736

Group type: EXPERIMENTAL
Intervention: Splinting before full-mouth disinfection (FMD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Splinting after full-mouth disinfection (FMD)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 34
Study: 34257959

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at 1200 mg every 12 hours for 48 hours
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 64
Study: 35605807

Group type: EXPERIMENTAL
Intervention: Organ transplantation
Number of subjects: 4178

Group type: COMPARATOR
Intervention: Steroid use
Number of subjects: 4178
Study: 34877262

Group type: EXPERIMENTAL
Intervention: Self-guided Internet-delivered intervention for coping with ADHD (N = 59)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Self-guided online psychoeducation (control group, N = 59)
Number of subjects: 118
Study: 34686624

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training during resistance exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercises alone (Control)
Number of subjects: 20
Study: 35982485

Group type: EXPERIMENTAL
Intervention: ImpACT + intervention (six once-a-week coping intervention sessions and six monthly maintenance sessions)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control condition (three weekly sessions of adapted problem-solving therapy)
Number of subjects: 350
Study: 33982092

Group type: EXPERIMENTAL
Intervention: Circulating linoleic acid (LA)
Number of subjects: 33126

Group type: EXPERIMENTAL
Intervention: Higher genetically predicted circulating arachidonic acid (AA)
Number of subjects: 33126
Study: 32954846

Group type: EXPERIMENTAL
Intervention: Volatile Organic Products (VOPs)
Number of subjects: 30
Study: 36072875

Group type: EXPERIMENTAL
Intervention: Hybutimibe plus atorvastatin
Number of subjects: 255

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 255
Study: 33558344

Group type: EXPERIMENTAL
Intervention: Transitional care intervention performed by geriatric-experienced care professionals for up to 12 months, including an individual care plan, personal visits, and telephone contacts.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transitional care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual discharge planning and usual ambulatory care (Control group)
Number of subjects: 0
Study: 35557075

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (spinning at 85% of maximal heart rate reserve)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Stretching (active control intervention)
Number of subjects: 42
Study: 34002642

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with or without ligament reconstruction with tendon interposition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Total joint arthroplasty using a Touch® implant
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isolated trapeziectomy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ligament reconstruction with tendon interposition
Number of subjects: 18
Study: 34232582

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 30-70 mg/d (mean 59.1 ± 14.8 mg/d)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 33354956

Group type: EXPERIMENTAL
Intervention: Qianlie Beixi Capsules combined with Magnetic Resonance Electromagnetic Therapy (MREM)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Qianlie Beixi Capsules (QBC)
Number of subjects: 124
Study: 34791789

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine cream delivered by fractional CO2 laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Topical clobetasol cream
Number of subjects: 22
Study: 33546304

Group type: EXPERIMENTAL
Intervention: HESPER Web
Number of subjects: 308

Group type: COMPARATOR
Intervention: Self-selected study sample
Number of subjects: 308
Study: 36106832

Group type: EXPERIMENTAL
Intervention: Menstrual Cycle (MC) phases
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral Contraceptive (OC) users
Number of subjects: 40
Study: 36644237

Group type: EXPERIMENTAL
Intervention: Efruxifermin 50 mg once-weekly for 16 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33821769

Group type: EXPERIMENTAL
Intervention: Self-oriented threat present, other-oriented threat present, efficacy present
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Self-oriented threat absent, other-oriented threat present, efficacy present
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Self-oriented threat present, other-oriented threat absent, efficacy present
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Self-oriented threat present, other-oriented threat present, efficacy absent
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Self-oriented threat absent, other-oriented threat absent, efficacy present
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Self-oriented threat absent, other-oriented threat present, efficacy absent
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Self-oriented threat present, other-oriented threat absent, efficacy absent
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Self-oriented threat absent, other-oriented threat absent, efficacy absent
Number of subjects: 324
Study: 36129617

Group type: EXPERIMENTAL
Intervention: Online transitional care communication skills training (OTCCST)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination of OTCCST and transitional care (TC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 33407590

Group type: EXPERIMENTAL
Intervention: ETA+MTX
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo+MTX
Number of subjects: 68
Study: 35562596

Group type: EXPERIMENTAL
Intervention: Deep learning combined with traditional radiomics methods
Number of subjects: 276

Group type: COMPARATOR
Intervention: Radiologists' diagnostic performance
Number of subjects: 276
Study: 34360146

Group type: EXPERIMENTAL
Intervention: Vibration (V)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No vibration (NV)
Number of subjects: 31
Study: 35791938

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 100
Study: 34776925

Group type: EXPERIMENTAL
Intervention: Dance Intervention (DI)
Number of subjects: 68
Study: 33407189

Group type: EXPERIMENTAL
Intervention: Reablement training program 'Stay Active at Home' for homecare staff
Number of subjects: 154
Study: 32587397

Group type: EXPERIMENTAL
Intervention: EDTA + PUI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: QMiX + PUI
Number of subjects: 80

Group type: COMPARATOR
Intervention: EDTA + CI
Number of subjects: 80

Group type: COMPARATOR
Intervention: QMiX + CI
Number of subjects: 80
Study: 35810980

Group type: EXPERIMENTAL
Intervention: Instrumental Variables (IV) methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider preference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV methods
Number of subjects: 0
Study: 33333440

Group type: EXPERIMENTAL
Intervention: Coping Internalized Stigma Program (PAREI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 32881765

Group type: EXPERIMENTAL
Intervention: TXA (2 g) administered prior to hospital arrival, less than 2 hours postinjury.
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: TXA (2 g) administered less than 45 minutes postinjury.
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo administered prior to hospital arrival, less than 2 hours postinjury.
Number of subjects: 287
Study: 34117788

Group type: EXPERIMENTAL
Intervention: Lu AG06466
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 32840126

Group type: EXPERIMENTAL
Intervention: Reishi & Privet Formula (RPF) 3.36 g/day for 6 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Reishi & Privet Formula (RPF)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 36289483

Group type: EXPERIMENTAL
Intervention: Simulated-experience format (interactive simulation)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Descriptive format (fact box)
Number of subjects: 600
Study: 33330913

Group type: EXPERIMENTAL
Intervention: Bovine colostrum/egg supplementation (BC/egg)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Corn/soy flour (control)
Number of subjects: 277
Study: 36369513

Group type: EXPERIMENTAL
Intervention: SWiM-C
Number of subjects: 388

Group type: COMPARATOR
Intervention: Standard advice
Number of subjects: 388
Study: 32567789

Group type: EXPERIMENTAL
Intervention: Extended early intervention (EI) for psychosis
Number of subjects: 220

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Extended EI (satisfied group)
Number of subjects: 220
Study: 32380983

Group type: EXPERIMENTAL
Intervention: Computable phenotype for ADHF
Number of subjects: 938

Group type: COMPARATOR
Intervention: ICD-9 codes for Acute Heart Failure
Number of subjects: 938

Group type: COMPARATOR
Intervention: All Heart Failure codes (ICD-9)
Number of subjects: 938
Study: 34538272

Group type: EXPERIMENTAL
Intervention: SELFIE (digital guided self-help intervention administered through a smartphone-based app, blended with three training sessions over a 6-week period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 33200214

Group type: EXPERIMENTAL
Intervention: ACTsmart intervention (guided smartphone-delivered Acceptance and Commitment Therapy) for 8 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ACTsmart intervention
Number of subjects: 34
Study: 32956694

Group type: EXPERIMENTAL
Intervention: 15 mg estetrol / 3 mg drospirenone (E4/DRSP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 30 mcg ethinylestradiol / 150 mcg levonorgestrel (EE/LNG)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 20 mcg ethinylestradiol / 3 mg drospirenone (EE/DRSP)
Number of subjects: 101
Study: 34143278

Group type: EXPERIMENTAL
Intervention: CORDIS (body-focused group therapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Guided self-help group (SHG)
Number of subjects: 53
Study: 34889742

Group type: EXPERIMENTAL
Intervention: MumMoodBooster (MMB)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Face-to-face Cognitive Behavioral Therapy (FTF-CBT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 116
Study: 33441095

Group type: EXPERIMENTAL
Intervention: Standard balloon kyphoplasty (BKP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tektona® (TEK)
Number of subjects: 14
Study: 33939383

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise with dietary modification
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resistance exercise with dietary modification
Number of subjects: 35
Study: 32446591

Group type: EXPERIMENTAL
Intervention: Articulator model surgery (AMS) with an intermediate occlusal splint made of acrylic resin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Virtual surgical planning (VSP) with the same intermediate splint fabricated using rapid prototyping technology
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both AMS and VSP
Number of subjects: 30
Study: 35954786

Group type: EXPERIMENTAL
Intervention: Professional development program of Project GIFT
Number of subjects: 2031

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2031
Study: 33484335

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (HCHO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mixed-macronutrient meal (MM)
Number of subjects: 15
Study: 32289193

Group type: EXPERIMENTAL
Intervention: Well-being therapy (WBT)
Number of subjects: 64
Study: 35316669

Group type: EXPERIMENTAL
Intervention: Mood stabilizer combined with antidepressant
Number of subjects: 104

Group type: COMPARATOR
Intervention: Mood stabilizer
Number of subjects: 104
Study: 33186665

Group type: EXPERIMENTAL
Intervention: Independent reviewer assessment of any RHD
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Independent reviewer assessment of definite RHD
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Independent reviewer assessment of borderline RHD
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement on the presence of any RHD
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for specific 2012 WHF classification
Number of subjects: 784
Study: 34857667

Group type: EXPERIMENTAL
Intervention: Skyflow device
Number of subjects: 192

Group type: COMPARATOR
Intervention: Solitaire FR stent
Number of subjects: 192
Study: 32527153

Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control group (patients receiving anti-TNF for IBD for other conditions)
Number of subjects: 343
Study: 35763494

Group type: EXPERIMENTAL
Intervention: 3D endoscopic video
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2D endoscopic video
Number of subjects: 62

Group type: COMPARATOR
Intervention: Microscopic video
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2D and 3D endoscopic videos
Number of subjects: 62
Study: 32507151

Group type: EXPERIMENTAL
Intervention: PNF contract-relax technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 30
Study: 36099977

Group type: EXPERIMENTAL
Intervention: Continuous ECG monitoring for 7 days at start of the study (t=0), after one (t=1) and 2 years (t=2).
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Usual diagnostic care procedures.
Number of subjects: 1860
Study: 34441942

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN) with Peri‐Olimel N4‐E
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional fluid therapy (FT)
Number of subjects: 158
Study: 35848154

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Total Knee Arthroplasty (RA-TKA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional Manual Total Knee Arthroplasty (CM-TKA)
Number of subjects: 72
Study: 33813352

Group type: EXPERIMENTAL
Intervention: Integrated personalized feedback intervention (PFI)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 125
Study: 33434271

Group type: EXPERIMENTAL
Intervention: Epilepsy Journey (gamified, online learning environment with 10 modules targeting EF deficits)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Epilepsy Journey
Number of subjects: 39
Study: 33036638

Group type: EXPERIMENTAL
Intervention: Octyl-2-cyanoacrylate tissue adhesive alone (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tissue adhesive after continuous subcuticular suture (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Skin staples (Group C)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 32
Study: 35029238

Group type: EXPERIMENTAL
Intervention: Afatinib monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of afatinib and HAD-B1
Number of subjects: 0
Study: 34970203

Group type: EXPERIMENTAL
Intervention: Zonisamide (25 mg per day) before bedtime for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35887937

Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Community-based periodontal care
Number of subjects: 140
Study: 34889293

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy (3 sessions per week for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting group (no intervention)
Number of subjects: 40
Study: 34819347

Group type: COMPARATOR
Intervention: Routine Manual Control (RMC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SPOCold with 2s averaging time
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SPOCnew with 2s averaging time
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SPOCold with 8s averaging time
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SPOCnew with 8s averaging time
Number of subjects: 24
Study: 32265057

Group type: EXPERIMENTAL
Intervention: VB-111 and paclitaxel (therapeutic dose 80 mg/m2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: VB-111 and paclitaxel (therapeutic dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sub-therapeutic dose of VB-111 and paclitaxel
Number of subjects: 21
Study: 33389627

Group type: EXPERIMENTAL
Intervention: Robot-assisted arthroplasty (RAA)
Number of subjects: 199
Study: 36237183

Group type: EXPERIMENTAL
Intervention: Gut microbiome analysis in HUA patients
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Microbial biomarkers
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Combined model of microbial biomarkers and clinical factors
Number of subjects: 168
Study: 34325580

Group type: EXPERIMENTAL
Intervention: Health orientation (psychographic framework)
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Physical exercise behavior
Number of subjects: 1201
Study: 32099975

Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius M18 (SsM18) given once a day for 3 months (group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 58
Study: 35279078

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 4000 UI subcutaneously every other day (n = 67)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard of care (n = 67)
Number of subjects: 134
Study: 34856961

Group type: EXPERIMENTAL
Intervention: Racial Discrimination (RD)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Weight Discrimination (WD)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Pain Interference
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Pain Intensity
Number of subjects: 483
Study: 35758878

Group type: EXPERIMENTAL
Intervention: ALVAC/gp120 + MF59 vaccines
Number of subjects: 1893
Study: 33940998

Group type: EXPERIMENTAL
Intervention: Silk suture
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cyanoacrylate bio-adhesive
Number of subjects: 300
Study: 35482890

Group type: EXPERIMENTAL
Intervention: Self-rated authenticity
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Other-rated authenticity
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Rater's own authenticity
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Meta-perceptions of authenticity
Number of subjects: 4040
Study: 35734671

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 600 μg misoprostol
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 800 μg misoprostol
Number of subjects: 357

Group type: COMPARATOR
Intervention: 800 μg misoprostol vs 400 μg misoprostol
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Higher misoprostol dosage
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 357